好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

CEDNIK syndrome, a rare neuro-cutaneous disorder
Child Neurology and Developmental Neurology
P1 - Poster Session 1 (5:30 PM-6:30 PM)
7-050
NA
CEDNIK (cerebral dysgenesis, neuropathy, ichthyosis and keratoderma) syndrome is a rare autosomal recessive neuro-cutaneous disorder characterized by mutation in Synaptosomal-associated protein 29 (SNAP29) gene. We present a patient with alteration in SNAP29.
Case report.

A 26-month old male born to non-consanguineous parents without any prenatal complications, had severe retrognathia at birth requiring G-tube placement and mandibular enhancement procedure. He had severe developmental delay with inability to sit, no speech development, severe cognitive issues and seizures developed at 9 months. Examination showed bilateral epicanthic folds with mid-facial hypoplasia, generalized icthyosis and diffuse hypotonia. MRI showed multiple brain malformations including partial agenesis of corpus callosum and diffuse polymicrogyria. A sequencing panel showed two mutations, a homozygous pathogenic frame shifts sequence change in the SNAP29 gene, associated with the CEDNIK syndrome. He has continued to have profound developmental delay and at 2 years is functioning in the 4-6 month range.

 

Our patient’s DNA analysis of SNAP29 gene demonstrated a homozygous one base pair duplication in exon 2, c.354dup. This pathogenic sequence change results in an amino acid frameshift and creates a premature stop codon 14 amino acids downstream of the mutation, p.Leu119Alafs*15. This pathogenic change is predicted to result in an abnormal transcript, causing truncated SNAP29 protein with abnormal function.

 

SNAP proteins are t-SNARE proteins that function in intracellular vesicle fusion. SNAP29 has been determined to bind to a broad range of syntaxin fusion proteins and is involved in a number of intracellular transport steps and would impact a variety of neuroectodermal tissues. Recent study suggest that SNAP has additional role as a negative modulator of neurotransmitter release by slowing the recycling of the SNARE-associated fusion machinery and synaptic vesicle turnover. This may be related to the severe neurologic al manifestations shown by patients with CEDNIK syndrome. 

Authors/Disclosures
Harmanpreet Tiwana, MD
PRESENTER
No disclosure on file
Gerald Raymond, MD (Johns Hopkins) Dr. Raymond has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Bluebird bio. Dr. Raymond has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. Raymond has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Travere. Dr. Raymond has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant with Dept of HHS.
Ashutosh Kumar, MD (Penn State Health) Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for PTC therapeutics. Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sarepta. Dr. Kumar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Kumar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Kumar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for PTC therapeutics. Dr. Kumar has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for American Academy of Pediatrics. The institution of Dr. Kumar has received research support from PTC therapeutics. The institution of Dr. Kumar has received research support from Sarepta Therapeutics. The institution of Dr. Kumar has received research support from Novartis/Avexis. The institution of Dr. Kumar has received research support from Fibrogen . The institution of Dr. Kumar has received research support from Biohaven. The institution of Dr. Kumar has received research support from Genentech. The institution of Dr. Kumar has received research support from MDA. Dr. Kumar has received personal compensation in the range of $500-$4,999 for serving as a Draft Report Reviewer/consultant with ECRI/Atheneum/QTC commercial services LLC/Connected Research and consulting/Vox.Bio.